secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037597
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q2 net loss $123.7M; advances CRISPR pipeline with Phase 2 enrollment for NTLA-2002 completed
--------------------------------------------------------------------------------

- Cash, equivalents and securities $1.1B at June 30, 2023, down from $1.3B at Dec 31, 2022.
- Net loss $123.7M in Q2 2023 vs $100.7M in Q2 2022; R&D expenses rose to $115.3M.
- All patients identified for NTLA-2002 Phase 2 study; pivotal Phase 3 planned for Q3 2024.
- NTLA-2001 IND submission for ATTR-CM expected in September; global pivotal study targeted by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/0000950170-23-037597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/ntla-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer